Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects

Published:2013-10-21 Issue:5 Volume:76 Page:776-786
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Frost Charles¹,Nepal Sunil¹,Wang Jessie¹,Schuster Alan¹,Byon Wonkyung²,Boyd Rebecca A.²,Yu Zhigang¹,Shenker Andrew¹,Barrett Yu Chen¹,Mosqueda‐Garcia Rogelio¹,LaCreta Frank¹

Affiliation:

1. Bristol‐Myers Squibb Princeton NJ USA

2. Pfizer Inc Groton CT USA

Funder

Bristol-Myers Squibb

Pfizer Inc

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12106

Reference34 articles.

1. Antithrombotic Therapy for VTE Disease

2. Limitations of Traditional Anticoagulants

3. Thrombotic events during oral anticoagulant treatment: results of the inception‐cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy);Palareti G;Thromb Haemost,1997

4. Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors

5. Visions & Reflections Factor Xa - a promising target for drug development

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Massive Pulmonary Embolism Related to a Patient With Heart Failure Secondary to Stress Cardiomyopathy: A Case Report;Cureus;2024-01-26

2. Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens;Scientific Reports;2023-12-27

3. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study;Drug Safety;2023-12-23

4. Differences in coagulation responses to vascular injury between uninterrupted dabigatran and apixaban - a clinical prospective randomized study;2023-12-19

5. Physiologically based pharmacokinetic modeling of apixaban to predict exposure in populations with hepatic and renal impairment and elderly populations;European Journal of Clinical Pharmacology;2023-12-15